Trial intelligence / Profile preview

Gadopiclenol vs Gadobutrol for MRI Diagnosis of Perianal Fistula in Crohn's Disease

2025-523278-18-00Phase 4Authorised

Sponsor: Vall d'Hebron Research Institute
Start: Dec 2025
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
Countries: 1

Overview

Phase 4, randomised trial of gadopiclenol and gadobutrol in anal fistula (2 arms), sponsored by Vall d'Hebron Research Institute. Primary endpoint: Correct detection of perianal fistula tract on MRI. Planned start Dec 2025; status: authorised.

Drugs

gadopiclenolgadobutrol

Conditions

anal fistula

Beyond the preview

Go deeper on 2025-523278-18-00.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2025-523278-18-00.